| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Specneuzhenide targets multiple proteins including Bcl-xL (Kd = 2.4 nM) and IL-2 (Kd = 2.59 nM). It inhibits hypoxia-induced VEGFA secretion and HIF-1α expression. The compound has anti-angiogenic properties. Specneuzhenide prevents oxidative injury in liver cells by maintaining mitochondrial membrane potential, possibly through induction of autophagy. It inhibits the production of inflammatory mediators in mouse macrophages by inhibiting lipid peroxidation. The compound reduces neurotoxicity.
|
|---|---|
| ln Vitro |
In vitro, Specneuzhenide (25, 50, and 100 μM) inhibits hypoxia-induced VEGFA secretion, VEGFA and PHD-2 mRNA expression, and protein levels of VEGFA, HIF-1α. The compound shows binding affinity to Bcl-xL (Kd = 2.4 nM) and IL-2 (Kd = 2.59 nM). It prevents oxidative injury in liver cells by maintaining mitochondrial membrane potential. Specneuzhenide inhibits inflammatory mediator production in mouse macrophages by inhibiting lipid peroxidation. The compound reduces neurotoxicity. Its anti-tumor and anti-angiogenic activities have been demonstrated in various cell-based assays.
|
| ln Vivo |
In vivo, Specneuzhenide has demonstrated anti-tumor activity, anti-angiogenic properties, and vision improvement effects. The compound supports liver function and may contribute to bone health by influencing osteoblast activity. Its pharmacological profile shows potential in cardiovascular and neurological disease research. Specneuzhenide prevents oxidative injury in liver cells. Further in vivo studies are ongoing to fully characterize its therapeutic potential. The compound is typically administered orally in preclinical studies.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Specneuzhenide involve measuring binding affinity to Bcl-xL and IL-2 using surface plasmon resonance or isothermal titration calorimetry (Kd = 2.4 nM and 2.59 nM, respectively). For anti-angiogenic activity, VEGFA and HIF-1α expression is measured by ELISA or Western blot. Anti-inflammatory activity is assessed by measuring lipid peroxidation and inflammatory mediator production in macrophages. Assays are performed in appropriate buffer systems with positive controls. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for Specneuzhenide are conducted in various cell lines including liver cells, macrophages, and cancer cells. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with Specneuzhenide at varying concentrations (e.g., 25, 50, and 100 μM). For hypoxia studies, cells are exposed to hypoxic conditions. VEGFA, HIF-1α, and PHD-2 levels are measured by ELISA or Western blot. Cell viability is assessed by MTT assay. Apoptosis is evaluated by Annexin V/PI staining. Experiments are performed in triplicate with appropriate controls.
|
| Animal Protocol |
In vivo animal studies for Specneuzhenide are conducted in rodent models of cancer, inflammation, and oxidative stress. For anti-tumor studies, tumor-bearing mice are treated with Specneuzhenide via oral administration. Tumor growth is monitored by caliper measurements. For anti-inflammatory studies, animal models of inflammation are used. For liver protection studies, models of oxidative liver injury are employed. For bone health studies, osteoblast activity is assessed. Dosing regimens are optimized based on pharmacokinetic data. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis.
|
| ADME/Pharmacokinetics |
Specneuzhenide (MW 686.65 g/mol, C31H42O17) is a phenolic glycoside with favorable solubility in DMSO (≥100 mg/mL). The compound is a natural product isolated from Ligustrum sinense. It has shown oral bioavailability in preclinical studies. Specneuzhenide is metabolized by hepatic enzymes. The compound is distributed to tissues including liver, as evidenced by its hepatoprotective effects. Pharmacokinetic parameters such as Cmax, Tmax, and half-life would be determined in species-specific studies. The compound shows stability under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Specneuzhenide is generally well-tolerated in preclinical studies. The compound is a natural phenolic glycoside derived from Ligustrum sinense. It has demonstrated hepatoprotective and anti-inflammatory effects with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
Specneuzhenide is a phenolic glycoside isolated from Ligustrum sinense with anti-tumor, anti-angiogenic, and vision improvement effects. It inhibits hypoxia-induced VEGFA secretion and HIF-1α expression. The compound has binding affinity to Bcl-xL (Kd = 2.4 nM) and IL-2 (Kd = 2.59 nM). Specneuzhenide prevents oxidative injury in liver cells by maintaining mitochondrial membrane potential. It inhibits inflammatory mediator production in macrophages. The compound reduces neurotoxicity. All applications are limited to non-human research use.
|
| Molecular Formula |
C31H42O17
|
|---|---|
| Molecular Weight |
686.65498
|
| Exact Mass |
686.242
|
| CAS # |
449733-84-0
|
| PubChem CID |
11146840
|
| Appearance |
White to off-white solid powder
|
| Density |
1.53±0.1 g/cm3 (20 ºC 760 Torr)
|
| LogP |
-2.2
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
48
|
| Complexity |
1120
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C/C=C\1/[C@@H](C(=CO[C@H]1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)C(=O)OC)CC(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OCCC4=CC=C(C=C4)O)O)O)O
|
| InChi Key |
STKUCSFEBXPTAY-GSUVRYNNSA-N
|
| InChi Code |
InChI=1S/C31H42O17/c1-3-16-17(18(28(41)42-2)12-45-29(16)48-31-27(40)24(37)22(35)19(11-32)46-31)10-21(34)44-13-20-23(36)25(38)26(39)30(47-20)43-9-8-14-4-6-15(33)7-5-14/h3-7,12,17,19-20,22-27,29-33,35-40H,8-11,13H2,1-2H3/b16-3-/t17-,19+,20+,22+,23+,24-,25-,26+,27+,29-,30+,31-/m0/s1
|
| Chemical Name |
methyl (4S,5Z,6S)-5-ethylidene-4-[2-oxo-2-[[(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)ethoxy]oxan-2-yl]methoxy]ethyl]-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~145.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4563 mL | 7.2816 mL | 14.5632 mL | |
| 5 mM | 0.2913 mL | 1.4563 mL | 2.9126 mL | |
| 10 mM | 0.1456 mL | 0.7282 mL | 1.4563 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
